Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HuoXue LiShui Formula for Chronic Subdural Hematoma
NCT06427980Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Feb 2025
- Primary completion
- Dec 2025
- Modality
- HM (Herbal Medicine)
- Countries
- 1
01
Overview
Randomised, double-blind trial of HuoXue LiShui in chronic subdural hematoma (CSDH) (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Rate of operation at 24 weeks. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
HuoXue LiShui
03
Conditions
chronic subdural hematoma (CSDH)
Beyond the preview
Go deeper on NCT06427980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06427980.